08:20:05 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-13 Kvartalsrapport 2024-Q3
2024-08-21 Kvartalsrapport 2024-Q2
2024-05-15 Kvartalsrapport 2024-Q1
2024-03-28 Ordinarie utdelning CESSA 0.00 DKK
2024-03-27 Årsstämma 2024
2024-02-29 Bokslutskommuniké 2023
2023-11-16 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-12 Kvartalsrapport 2023-Q1
2023-03-24 Ordinarie utdelning CESSA 0.00 DKK
2023-03-23 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-18 Kvartalsrapport 2022-Q3
2022-11-04 Extra Bolagsstämma 2022
2022-08-19 Kvartalsrapport 2022-Q2
2022-04-19 Kvartalsrapport 2022-Q1
2022-03-18 Ordinarie utdelning CESSA 0.00 DKK
2022-03-17 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-19 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-04-19 Kvartalsrapport 2021-Q1
2021-03-29 Ordinarie utdelning CESSA 0.00 DKK
2021-03-26 Årsstämma 2021
2021-02-11 Bokslutskommuniké 2020

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriBioteknik
Cessatech är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom forskning och utveckling av smärtstillande nässpray som vidare används för behandling av akuta smärttillstånd hos barn. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och relaterade produkter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Huvudkontoret ligger i Köpenhamn.
2022-08-11 08:30:00

We are finally entering a very exciting period for the company, as we will soon have first patient in our pivotal trial 0205, a trial that will investigate the postoperative analgesic efficacy of CT001.
We obtained regulatory approval by the authorities and thereby green light at the end of June and have since then prepared the site and involved dental clinics. We are ready and hope to announce first patient within a few weeks. This will basically take the company to the next level as not that many companies are in a late-stage clinical development... 

Upcoming top line results of Trial 0206
During this quarter (Q3) we also anticipate to announce the top-line results of trial 0206, the study completed recruitment earlier this year and is currently undergoing statistical analysis.  The trial investigates pharmacokinetics of CT001 in children aged 1-17 undergoing elective surgical procedures. The results will be very important in the work going forward and we are very excited that we soon have the results.

Developing the Team - welcome to Martin, head of CMC & Device
CMC & Device development is instrumental, so we are very fortunate to have Martin joining us earlier this year. Martin has a Ph.D. in Chemistry and a postdoc from Harvard prior to joining Lundbeck where he worked for 14 years, while also obtaining a degree in Pharmaceutical Medicine. He is both as a CMC subject-matter-expert, has 12 years of project management experience & been involved in 15 IMPD/IND submissions.

Entrepreneurship award donated to Rigshospitalet
We donated the prize money we won from the Rotary entrepreneurship award to Rigshospitalet and bought Toy's for the Children - children are often waiting or hospitalised for longer periods and especially if they are frequent visiting due to for instance chronic conditions. On the picture is Laura, and when the picture was taken, she had been anaesthetised for the 37th time at Rigshospitalet. Happy that we can make a small difference….and thanks to the Rotary Club for awarding and selecting us as district winners for our entrepreneurship.